← Leaderboards
Leslie S Kean
Emory University
$43,609,566
Attributed
$47,607,768
Total exposure
21
Grants
19
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$45,908,139 · 20
FDA$1,699,629 · 1
By mechanism
U19$17,698,756 · 8
R01$17,024,373 · 3
P01$5,104,381 · 4
U01$3,995,050 · 1
R33$1,647,909 · 1
UG1$1,077,501 · 2
Top collaborators
- Michael A Pulsipher5 shared
- Alan S. Wayne3 shared
- Heather E Stefanski2 shared
- Michael R Verneris2 shared
- Ami Siddharth Bhatt1 shared
- Miguel-Angel Perales1 shared
Most similar at Emory University
Same institution · by research overlap
- Edmund K. Waller$12,096,498
- Francois J Villinger$61,853,654
- Robert A. Bednarczyk$4,512,756
Others in their field
Top investigators on “Transplant Recipients”
- Leland H Hartwell · Fred Hutchinson Cancer Research Center$84,240,435
- Peter Scott Heeger · Case Western Reserve University$83,635,934
- Joren C Madsen · Massachusetts General Hospital$58,876,734
- Mary M Horowitz · Medical College Of Wisconsin$55,693,586
- Peter G Stock · University Of California San Francisco$39,243,787
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$38,722,226
Research focus
Transplant RecipientsT-LymphocyteDesignImmuneTransplantationImmunityRegimenBaseImmune ToleranceLifeCellsMorbidity - Disease RateNonhuman PrimateToxic EffectSuccessChronicImmunologicsInsightImmunosuppressionRegulatory T-LymphocyteMortalityMacaca MulattaProceduresMolecular
Grant awards (77)
Optimizing HCT Outcomes: A Multi-omic Investigation$2,024,340
R01 · FY2025 · HL · contact PI
Novel Biologic Therapies for GVHD$1,141,368
R01 · FY2025 · HL · contact PI
Molecular Immunology Core$659,958
U19 · FY2025 · AI · contact PI
Project 2: The New Era of Cellular Therapies For Lung Transplant Tolerance$659,957
U19 · FY2025 · AI · contact PI
Project 2: Next-Generation Mixed Chimerism Induction for Heart Allograft Tolerance$646,162
P01 · FY2025 · HL · contact PI
Defining the T Cell Mediators of Clinical Response in Chronic GVHD$466,164
P01 · FY2025 · HL · contact PI
BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening Diseases$164,548
UG1 · FY2025 · HL
Novel Biologic Therapies for GVHD$1,118,541
R01 · FY2024 · HL · contact PI
Project 2: The New Era of Cellular Therapies For Lung Transplant Tolerance$1,033,278
U19 · FY2024 · AI · contact PI
Project 2: Next-Generation Mixed Chimerism Induction for Heart Allograft Tolerance$636,457
P01 · FY2024 · HL · contact PI
Molecular Immunology Core$530,837
U19 · FY2024 · AI · contact PI
Defining the T Cell Mediators of Clinical Response in Chronic GVHD$454,998
P01 · FY2024 · HL · contact PI
BMT Core - Pediatric Transplantation and Cellular Therapy Consortium (PTCTC): Providing Clinical Trial Access For Children With Life Threatening Diseases$184,489
UG1 · FY2024 · HL
Novel Biologic Therapies for GVHD$1,169,283
R01 · FY2023 · HL · contact PI
Project 2: The New Era of Cellular Therapies For Lung Transplant Tolerance$1,066,774
U19 · FY2023 · AI · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$989,251
U01 · FY2023 · AI
Project 2: Next-Generation Mixed Chimerism Induction for Heart Allograft Tolerance$646,162
P01 · FY2023 · HL · contact PI
Molecular Immunology Core$547,585
U19 · FY2023 · AI · contact PI
Defining the T Cell Mediators of Clinical Response in Chronic GVHD$466,272
P01 · FY2023 · HL · contact PI
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant Consortium$176,678
UG1 · FY2023 · HL · contact PI
Novel Biologic Therapies for GVHD$1,171,119
R01 · FY2022 · HL · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$995,166
U01 · FY2022 · AI
Project 2: Next-Generation Mixed Chimerism Induction for Heart Allograft Tolerance$646,162
P01 · FY2022 · HL · contact PI
Defining the T Cell Mediators of Clinical Response in Chronic GVHD$478,842
P01 · FY2022 · HL · contact PI
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant Consortium$180,228
UG1 · FY2022 · HL · contact PI
Novel Biologic Therapies for GVHD$1,251,101
R01 · FY2021 · HL · contact PI
Project 2: Next-Generation Mixed Chimerism Induction for Heart Allograft Tolerance$663,162
P01 · FY2021 · HL · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$526,140
U01 · FY2021 · AI
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant Consortium$183,889
UG1 · FY2021 · HL · contact PI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$18,548
U01 · FY2021 · AI
Randomized study of low versus moderate dose busulfan in transplant for severe combined immunodeficiency$1,465,945
U01 · FY2020 · AI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques -- (KEAN)$672,809
R01 · FY2020 · HL · contact PI
Unrelated Donor BMT vs. Immune Suppression for Newly Diagnosed Severe Aplastic Anemia in Children and Young Adults: BMT CTN Core Center Renewal for the Pediatric Blood and Marrow Transplant Consortium$187,669
UG1 · FY2020 · HL · contact PI
Defining HIV sanctuary sites during autologous and allogeneic transplantation$894,352
U19 · FY2019 · HL · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques -- (KEAN)$672,809
R01 · FY2019 · HL · contact PI
Defining HIV sanctuary sites during autologous and allogeneic transplantation$894,352
U19 · FY2018 · HL · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques -- (KEAN)$672,809
R01 · FY2018 · HL · contact PI
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation -- (KEAN)$544,343
R33 · FY2018 · AI · contact PI
Defining HIV sanctuary sites during autologous and allogeneic transplantation$894,352
U19 · FY2017 · HL · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques$672,809
R01 · FY2017 · HL · contact PI
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation$473,867
R33 · FY2017 · AI · contact PI
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation -- (KEAN)$73,914
R33 · FY2017 · AI · contact PI
Defining HIV sanctuary sites during autologous and allogeneic transplantation$894,352
U19 · FY2016 · HL · contact PI
Cellular Therapies for Tolerance Induction$878,662
U19 · FY2016 · AI · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques$742,484
R01 · FY2016 · HL · contact PI
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation$555,785
R33 · FY2016 · AI · contact PI
Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD$400,000
R01 · FY2016 · FD · contact PI
Integrated Molecular and Cellular Immunology Core$265,088
U19 · FY2016 · AI · contact PI
Ph2 Study of Abatacept w/CSA/Tac & Mtx for GVHD IND 111738 (03/17/2011)$99,630
R01 · FY2016 · FD · contact PI
Defining HIV sanctuary sites during autologous and allogeneic transplantation$816,005
U19 · FY2015 · HL · contact PI
Cellular Therapies for Tolerance Induction$534,359
U19 · FY2015 · AI · contact PI
Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD$399,999
R01 · FY2015 · FD · contact PI
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation$260,221
R21 · FY2015 · AI · contact PI
Integrated Molecular and Cellular Immunology Core$165,811
U19 · FY2015 · AI · contact PI
Cellular Therapies for Tolerance Induction$1,008,605
U19 · FY2014 · AI · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques$781,408
R01 · FY2014 · HL · contact PI
Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD$400,000
R01 · FY2014 · FD · contact PI
Curing HIV Through Allogeneic Hematopoietic Stem Cell Transplantation$323,513
R21 · FY2014 · AI · contact PI
Integrated Molecular and Cellular Immunology Core$225,983
U19 · FY2014 · AI · contact PI
Cellular Therapies for Tolerance Induction$936,927
U19 · FY2013 · AI · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques$756,300
R01 · FY2013 · HL · contact PI
Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD$377,580
R01 · FY2013 · FD · contact PI
Integrated Molecular and Cellular Immunology Core$322,948
U19 · FY2013 · AI · contact PI
Phase 2 Study of Abatacept with Calcineurin Inhibition and Methotrexate for GVHD$22,420
R01 · FY2013 · FD · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques$817,028
R01 · FY2012 · HL · contact PI
Cellular Therapies for Tolerance Induction$675,276
U19 · FY2012 · AI · contact PI
Integrated Molecular and Cellular Immunology Core$579,940
U19 · FY2012 · AI · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques$826,095
R01 · FY2011 · HL · contact PI
Adoptive Cellular Therapies to Enhance Tolerance and Protective Immunity$687,484
U19 · FY2011 · AI · contact PI
Novel Biologic Therapies for BMT: Mechanistic Evaluation in Rhesus Macaques$834,441
R01 · FY2010 · HL · contact PI
Adoptive Cellular Therapies to Enhance Tolerance and Protective Immunity$691,150
U19 · FY2010 · AI · contact PI
Adoptive Cellular Therapies to Enhance Tolerance and Protective Immunity$1,039,099
U19 · FY2009 · AI · contact PI
Innate Immunity and Transplantatation Tolerance$121,716
K08 · FY2009 · AI · contact PI
Adoptive Cellular Therapies to Enhance Tolerance and Protective Immunity$795,622
U19 · FY2008 · AI · contact PI
Innate Immunity and Transplantatation Tolerance$121,716
K08 · FY2008 · AI · contact PI
Innate Immunity and Transplantation Tolerance$121,716
K08 · FY2007 · AI · contact PI
Innate Immunity and Transplantatation Tolerance$110,916
K08 · FY2006 · AI · contact PI